SAN FRANCISCO (MarketWatch) -- Oncolytics Biotech Inc. /zigman2/quotes/204741333/composite ONCY +1.56% /zigman2/quotes/203812837/delayed CA:ONC -0.60% shares rose 10% to $2.15 in Tuesday morning trade. The company said researchers will present data Tuesday showing that treatment of human colon cancer cell lines with the combination of Reolysin and gemcitabine resulted in both in vitro and in vivo synergy. There was no toxicity associated with the combined treatment, and tumors treated with the combination were significantly smaller than tumors in control groups or tumors treated with either agent alone, the company said. Oncolytics said in a statement that "the researchers concluded that the synergistic combination of Reolysin and gemcitabine is a promising therapeutic regimen for study in clinical trials." Reolysin is the company's proprietary formulation of the human reovirus.